Literature DB >> 25673889

Rifaximin: irritable bowel syndrome.

Joyce A Generali1, Dennis J Cada2.   

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

Entities:  

Year:  2014        PMID: 25673889      PMCID: PMC4319800          DOI: 10.1310/hpj4911-1014

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  9 in total

Review 1.  American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.

Authors:  Alexander C Ford; Paul Moayyedi; Brian E Lacy; Anthony J Lembo; Yuri A Saito; Lawrence R Schiller; Edy E Soffer; Brennan M R Spiegel; Eamonn M M Quigley
Journal:  Am J Gastroenterol       Date:  2014-08       Impact factor: 10.864

2.  Rifaximin therapy for patients with irritable bowel syndrome without constipation.

Authors:  Mark Pimentel; Anthony Lembo; William D Chey; Salam Zakko; Yehuda Ringel; Jing Yu; Shadreck M Mareya; Audrey L Shaw; Enoch Bortey; William P Forbes
Journal:  N Engl J Med       Date:  2011-01-06       Impact factor: 91.245

Review 3.  The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.

Authors:  Stacy B Menees; Monthira Maneerattannaporn; Hyungjin Myra Kim; William D Chey
Journal:  Am J Gastroenterol       Date:  2011-11-01       Impact factor: 10.864

4.  Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects.

Authors:  Mark Pimentel; Walter Morales; Kathleen Chua; Gillian Barlow; Stacy Weitsman; Gene Kim; Meridythe M Amichai; Venkata Pokkunuri; Emily Rook; Ruchi Mathur; Zachary Marsh
Journal:  Dig Dis Sci       Date:  2011-05-11       Impact factor: 3.199

Review 5.  Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?

Authors:  David J Farrell
Journal:  J Clin Gastroenterol       Date:  2013-03       Impact factor: 3.062

Review 6.  Irritable bowel syndrome: a concise review of current treatment concepts.

Authors:  Geoffrey C Wall; Ginelle A Bryant; Michelle M Bottenberg; Erik D Maki; Andrew R Miesner
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

7.  Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use.

Authors:  Mohammed Saadi; Richard W McCallum
Journal:  Ther Adv Chronic Dis       Date:  2013-03       Impact factor: 5.091

Review 8.  Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine.

Authors:  Lekha Saha
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

9.  Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.

Authors:  P Schoenfeld; M Pimentel; L Chang; A Lembo; W D Chey; J Yu; C Paterson; E Bortey; W P Forbes
Journal:  Aliment Pharmacol Ther       Date:  2014-04-03       Impact factor: 8.171

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.